Taking Wegovy for Weight Loss: What Really Happens

How does semaglutide actually reduce your weight?

Semaglutide works by mimicking GLP-1, a hormone your gut releases after eating. It binds to GLP-1 receptors in the brain and digestive system, dialling down appetite signals and slowing the rate at which food leaves your stomach. The result is that most people feel full sooner at meals and less drawn to snacking between them. Hunger becomes quieter rather than absent — a genuinely different feeling from dieting through willpower alone.

That biological shift is what makes the clinical results possible. In the STEP 1 trial, participants lost an average of around 15% of their starting body weight over 68 weeks, with the strongest losses seen in people who reached and stayed on the 2.4 mg maintenance dose. Weight is a condition shaped by physiology, and semaglutide addresses part of that physiology directly. The semaglutide overview on this site explains the mechanism in more detail if you want to go deeper.

It is worth being clear that the medicine works best alongside genuine lifestyle changes. Prescribers recommend a reduced-calorie diet and regular activity not as fine print but because the clinical trials were designed that way, the two reinforce each other. Protein intake, hydration and keeping active (including strength work where possible) matter more than ever when appetite is reduced and overall food volume falls.

What does the dosing journey look like from week one onwards?

The titration schedule is gradual by design. If you are wondering how you take Wegovy for weight loss, treatment begins at 0.25 mg weekly (a dose low enough that most people tolerate it well) then steps up roughly every four weeks through 0.5 mg, 1.0 mg and 1.7 mg before reaching the standard 2.4 mg maintenance dose. Your prescriber controls those steps based on how you are tolerating each level; nobody should rush the schedule to chase faster results.

Since January 2026, the MHRA has also approved a higher 7.2 mg dose for eligible adults. A dedicated single-dose 7.2 mg pen followed in April 2026, as confirmed by the MHRA's announcement on GOV.UK. That higher ceiling narrows the gap with tirzepatide results seen in head-to-head trials, though whether it is appropriate for you is entirely a clinical decision. If you are already on treatment elsewhere, our page on switching to or continuing Wegovy covers what transfer patients can expect.

A question our prescribers hear most weeks: "Can I stay on the lower dose forever if I feel fine?" The honest answer is that a lower maintenance dose may still produce meaningful weight loss for some people, but whether that is clinically appropriate and sustainable is something your prescriber reviews at each repeat, not a decision to make unilaterally.

Which side effects should you actually prepare for?

The side-effect profile of Wegovy is well documented and largely gastrointestinal. Nausea is the most commonly reported effect, particularly in the first weeks after starting or after a dose increase. Vomiting, diarrhoea, constipation and acid reflux appear less often but are established in the clinical data. Headache, fatigue and injection-site redness round out the list of common reactions. Most of these settle within days to a couple of weeks once the body adjusts.

Staying well hydrated matters more than usual if you are experiencing nausea or loose stools, reduced appetite can mean reduced fluid intake too. Eating smaller portions and avoiding fatty or spicy foods early in treatment is practical advice many people find useful, though your prescriber or pharmacist is the right person to tailor guidance to your situation.

Serious reactions are rare but should be taken seriously. Severe, persistent stomach pain that reaches the back, with or without vomiting, needs urgent medical attention because it can signal pancreatitis. The NHS semaglutide medicines page sets out the full list of side effects and the specific circumstances that warrant contacting a doctor the same day. Suspected side effects can also be reported directly to the MHRA at yellowcard.mhra.gov.uk.

Who can take Wegovy in the UK, and how does the private route work?

The licensed eligibility criteria are an adult BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability, contraindications, current medicines, and medical history all factor into a prescriber's decision.

On the NHS, Wegovy is available through specialist weight management services under NICE's appraisal TA875. Waiting lists at those services are commonly long, and eligibility criteria are strict. Private treatment through a regulated online pharmacy is the route most people take when they do not meet the NHS threshold, cannot wait, or simply prefer a faster process. For context on what private treatment costs and what a legitimate price should include, our Wegovy cost guide works through the numbers honestly.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not a system. If you are ready to understand your options fully, the Wegovy weight loss overview brings together the key facts, or you can explore all available treatments and speak to our prescribers about what suits you. Men sometimes have specific questions about how results compare, the Wegovy for men page covers that directly.